Drug Database · Clinicians

Human albumin

Brands (18) AlbuRx, Alburel, Albutein…Show all

US brand (reference label): ALBUMINEX; not a Philippine-registered brand.

Blood substitutes and plasma protein fractions; Plasma fraction for specific use PH FDA category

Rx · Prescription drug23 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 8428d373-f4b1-4e3b-bb19-ea89048f7c79, version date December 31, 2024 (ALBUMINEX · BPL). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Hypovolemia
  • Ascites
  • Hypoalbuminemia including from burns
  • Acute Nephrosis
  • Acute Respiratory Distress Syndrome (ARDS)
  • Cardiopulmonary Bypass
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE ALBUMINEX 5% is a 5% albumin solution indicated for adults and children: Hypovolemia (1.1) Ascites (1.2) Hypoalbuminemia including from burns (1.3) Acute Nephrosis (1.4) Acute Respiratory Distress Syndrome (ARDS) (1.5) Cardiopulmonary Bypass (1.6) 1.1 Hypovolemia ALBUMINEX 5% is indicated for restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated, and use of a colloid is appropriate e.g. hypovolemia following shock due to trauma or sepsis, in surgical patients and in other similar conditions with volume deficiency when restoration and maintenance of circulating blood volume is required in both adult and pediatric patients. In pediatric patients to reverse hypovolemia and achieve normal capillary refill time. 1, 2, 3, 4, 5, 6, 7, 8 1.2 Ascites ALBUMINEX 5% is indicated for prevention of central volume depletion and maintenance of cardiovascular function after large volume parencentesis in patients with liver cirrhosis or other chronic liver disease in adults and children. 9, 10, 11, 12 ALBUMINEX 5% infusion plus administration of vasoactive drugs is indicated in the treatment of type I hepatorenal syndrome. 6 For patients with spontaneous bacterial peritonitis ALBUMINEX 5% is indicated as adjuvant treatment to antibiotic therapy. 9, 10, 13 1.3 Hypoalbuminemia including from burns ALBUMINEX 5% is indicated in patients with severe burn injury (> 20% total body surface area), but not until at least 12 to 24 hours after the burn, in order to correct protein loss, decrease overall fluid requirements, decrease systemic edema and stabilize cardiovascular hemodynamics without fluid overload (initial resuscitation should be with crystalloids). 8, 14 ALBUMINEX 5% is also indicated in patients with pre- or post-operative hypoproteinemia and for third space protein loss due to infection or burns. 1.4 Acute Nephrosis ALBUMINEX 5% is indicated in patients with acute nephrosis in combination with loop diuretics to reinforce the diuretic therapeutic effect, which is reduced by hypoalbuminemia, and for the correction of reduced oncotic pressure. 15, 16 1.5 Acute Respiratory Distress Syndrome (ARDS) ALBUMINEX 5% is indicated in conjunction with diuretics to correct fluid volume overload associated with ARDS. 17, 18, 19 1.6 Cardiopulmonary Bypass ALBUMINEX 5% is indicated in cardiopulmonary bypass procedures as part of the priming fluids to passivate the synthetic surfaces of the extracorporeal circuit and maintain the patient's colloid oncotic pressure. 20, 21, 22, 23, 24, 25

Contraindications

4 CONTRAINDICATIONS ALBUMINEX 5% is contraindicated in patients with: Hypersensitivity to human albumin or any of the excipients Severe anemia or cardiac failure with normal or increased intravascular volume Hypersensitivity to human albumin or the excipients Severe anemia or cardiac failure with normal or increased intravascular volume

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label
  • For intravenous administration only. For intravenous use only. ALBUMINEX 5% may be diluted with 0.9% saline or 5% dextrose (glucose). Dosage and infusion rate should be adjusted to the patient's individual requirements. Indication Dose Hypovolemia Adults: Initial dose of 25 g (including renal dialysis). For acute liver failure: initial dose of 12 to 25 g. (2.1)
  • Prevention of central volume depletion after paracentesis due to cirrhotic ascites Adults: 8 g for every 1000 mL of ascitic fluid removed. (2.1)
  • Hypoalbuminemia including from burns Adults: 50 to 75 g For pre- and post-operative hypoproteinemia: 50 to 75 g. For burn therapy after the first 24 h: initial dose of 25 g and dose adjustment to maintain plasma protein concentration of 2.5 g per 100 mL. Third space protein loss due to infection: initial dose of 50 to 100 g. (2.1)
  • Acute nephrosis Adults: 25 g together with diuretic once a day for 7-10 days. (2.1)
  • Adult respiratory distress syndrome (ARDS) Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary. (2.1)
  • Cardiopulmonary bypass procedures Adults: Initial dose of 25 g. (2.1)
2.1 Dosage

2.1 Dosage The concentration of ALBUMINEX 5% used, its dosage, and infusion rate should be adjusted to the patient's individual requirements and clinical indication. Indication Dose Hypovolemia Hypovolemia Adults: Initial dose of 25 g. If hemodynamic stability is not achieved within 15 to 30 minutes, an additional dose may be given.

For acute liver failure: initial dose of 12 to 25 g. An infusion rate of 1-2 mL per minute is usually indicated. For renal dialysis; the initial dose should not exceed 25 g and patients should be carefully observed for signs of fluid overload. Prevention of central volume depletion after paracentesis due to cirrhotic ascites Adults: 8 g for every 1000 mL of ascitic fluid removed.

Hypoalbuminemia including from burns Adults: 50 to 75 g For pre- and post-operative hypoproteinemia: 50 to 75 g. In burns, therapy usually starts with administration of large volumes of crystalloid solution to maintain plasma volume. After 24 hours: initial dose of 25 g and dose adjustment to maintain plasma protein concentration of 2.5 g per 100 mL or a serum protein concentration of 5.2 g per 100 mL.

Third space protein loss due to infection or burns: initial dose of 50 to 100 g. An infusion rate of 1-2 mL per minute is usually indicated in the absence of shock. Treatment should always be guided by hemodynamic response. Acute nephrosis Adults: 25 g together with diuretic once a day for 7-10 days. Adult respiratory distress syndrome (ARDS) Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary.

Cardiopulmonary bypass procedures Adults: Initial dose of 25 g. Additional amounts may be administered as clinically indicated.

2.3 Administration

2.3 Administration Visually inspect the solution for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if there are any particulates seen or if the solution is discolored. If a large volume is infused, ensure that the vial is at room temperature before infusion.

Do not dilute with Sterile Water for Injection as hemolysis may occur. ALBUMINEX 5% may be diluted with 0.9% saline or 5% dextrose. Begin the infusion within 4 hours of piercing the vial stopper (the product does not contain any preservative). Adjust the rate of infusion according to the individual patient's hemodynamic and other physiological responses, using appropriate clinical monitoring.

Dosing: Altered kidney function

From the US FDA label · Dosage and administration (renal excerpts)

Indication Dose Hypovolemia Adults: Initial dose of 25 g (including renal dialysis).

Third space protein loss due to infection: initial dose of 50 to 100 g. ( 2.1 ) Acute nephrosis Adults: 25 g together with diuretic once a day for 7-10 days. ( 2.1 ) Adult respiratory distress syndrome (ARDS) Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary. ( 2.1 ) Cardiopulmonary bypass procedures Adults: Initial dose of 25 g. ( 2.1 ) 2.1 Dosage The concentration of ALBUMINEX 5% used, its dosage, and infusion rate should be adjusted to the patient's individual requirements and clinical indication.

For renal dialysis; the initial dose should not exceed 25 g and patients should be carefully observed for signs of fluid overload.

Acute nephrosis Adults: 25 g together with diuretic once a day for 7-10 days.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use No human or animal data. Use only if clearly needed.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use No human or animal data. Use only if clearly needed.

Administration

2.1 Dosage The concentration of ALBUMINEX 5% used, its dosage, and infusion rate should be adjusted to the patient's individual requirements and clinical indication. Indication Dose Hypovolemia Hypovolemia Adults: Initial dose of 25 g. If hemodynamic stability is not achieved within 15 to 30 minutes, an additional dose may be given. For acute liver failure: initial dose of 12 to 25 g. An infusion rate of 1-2 mL per minute is usually indicated. For renal dialysis; the initial dose should not exceed 25 g and patients should be carefully observed for signs of fluid overload. Prevention of central volume depletion after paracentesis due to cirrhotic ascites Adults: 8 g for every 1000 mL of ascitic fluid removed. Hypoalbuminemia including from burns Adults: 50 to 75 g For pre- and post-operative hypoproteinemia: 50 to 75 g. In burns, therapy usually starts with administration of large volumes of crystalloid solution to maintain plasma volume. After 24 hours: initial dose of 25 g and dose adjustment to maintain plasma protein concentration of 2.5 g per 100 mL or a serum protein concentration of 5.2 g per 100 mL. Third space protein loss due to infection or burns: initial dose of 50 to 100 g. An infusion rate of 1-2 mL per minute is usually indicated in the absence of shock. Treatment should always be guided by hemodynamic response. Acute nephrosis Adults: 25 g together with diuretic once a day for 7-10 days. Adult respiratory distress syndrome (ARDS) Adults: 25 g over 30 minutes and repeated at 8 hours for 3 days, if necessary. Cardiopulmonary bypass procedures Adults: Initial dose of 25 g. Additional amounts may be administered as clinically indicated.

2.3 Administration Visually inspect the solution for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if there are any particulates seen or if the solution is discolored. If a large volume is infused, ensure that the vial is at room temperature before infusion. Do not dilute with Sterile Water for Injection as hemolysis may occur. ALBUMINEX 5% may be diluted with 0.9% saline or 5% dextrose. Begin the infusion within 4 hours of piercing the vial stopper (the product does not contain any preservative). Adjust the rate of infusion according to the individual patient's hemodynamic and other physiological responses, using appropriate clinical monitoring.

US FDA label

Dosage forms

Philippines

  • Solution for iv infusion: 50 g/L, 200 g/L, 250 g/L
  • ) solution for intravenous infusion: 0.2 g/mL
  • ) solution for infusion: 0.2 g/mL, 200 mg/mL
  • Solution for infusion: 200 g/L
  • ): 50 g/L) Solution for Infusion (100 mL, 250 mL
  • ) solution for injection for iv infusion: 200 g/L

Registered products in the Philippines

23 products registered with the Food and Drug Administration (FDA) Philippines list Human albumin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products23
Philippine FDA-registered products for Human albumin
Package insert
AlbiominHuman Albumin
20% (200g/L) Solution for Injection for IV Infusion50 mL and 100 mL Clear, Colorless Type II (Ph. Eur.) Soda-Lime Silica Glass Vial with Bromobutyl Rubber Stopper (Type I Ph. Eur.) (Box of 1's)
Rx
Biotest Pharma GmbHGermany
EC Zuric Biotherapies, Inc.
BR-747
Sep 7, 2030
AlbumaxHuman Albumin
20% Solution for Injection (Iv)50 mL Glass Vial with Blue Flip-Off Cap (Box of 1's)
Rx
GC Biopharma Corp.Republic of Korea
Vizcarra Pharmaceutical, Incorporated
BR-459
May 23, 2031
AlbunormHuman Albumin
5% (50g/L) Solution for Infusion (100 mL, 250 mL)100 mL and 250 mL of Solution in Infusion bottle (Type II glass) with bromobutyl rubber stopper (Box of 1's)
Rx
Octapharma Produktionsgesellschaft Deutschland mbHGermany
Medlink Marketing Inc.Importer: Zenith Bloom Company Inc.
BR-1173
Sep 5, 2031
Albunorm 20%Human Albumin
200 g/L (20% w/v) Solution for Infusion (IV)50 mL Solution in Infusion Bottle (Type II Glass) with Bromobutyl Rubber Stopper (Box of 1’s)
Rx
Octapharma Produktionsgesellschaft Deutschland mbHGermany
Medlink Marketing Inc.Importer: Zenith Bloom Company Inc.
BR-1165
Jul 26, 2031
Albunorm 25%Human Albumin
250 g/L (20% w/v) Solution for IV infusionType II infusion glass bottle with bromobutyl rubber stopper x 50 mL and l00 mL (Box of 1’s)
Rx
OctapharmaFrance
Medlink Marketing Inc.Importer: Zenith Bloom Company Inc.
BR-1157
Jun 6, 2031
Albunorm 5%Human Albumin
50 g/L Solution for IV Infusion (I.V.)Type II glass infusion with bromobutyl rubber stopper x 500 mL (Box of 1's)
Rx
Octapharma ABSweden
Medlink Marketing Inc.Importer: Zenith Bloom Company Inc.
BR-1174
Sep 5, 2031
AlburelHuman Albumin
20 % w/v (200 mg/mL) Solution for Infusion (IV)50 mL and 100 mL Type I Clear and Colorless Glass Vial with Light Brown-Colored Flip-off Cap (Box of 1's)
Rx
Reliance Life Sciences Pvt. Ltd.India
Ambica International Corporation
BRP-048
Apr 5, 2030
AlburelHuman Albumin
20% (0.2 g/mL) Solution for Intravenous Infusion50 mL and 100 mL Clear, Colorless Type I Glass Vial (Box of 1's)
Rx
Reliance Life Sciences Pvt. Ltd.India
Ambica International CorporationImporter: Ambicare Pharmaceuticals Inc.
BRP-057-02
May 9, 2029
AlbuRxHuman Albumin
200 g/L (20% w/v) Solution for IV InfusionSingle dose. Type II glass vial with rubber stopper and yellow polypropylene flip-off disc (10 g in 50 mL Solution; 20 g in 100 mL solution) (Box of 1's)
Rx
CSL Behring AGSwitzerland
Zuellig Pharma Corporation
BR-1275
Jun 7, 2028
AlbuRxHuman Albumin
200 g/L (20% w/v) Solution for IV InfusionSingle dose. Type II glass vial with rubber stopper and yellow polypropylene flip-off disc (10 g in 50 mL Solution) (Box of 1's)
Rx
CSL Behring LLCUSA
Zuellig Pharma Corporation
BR-1277
Jun 7, 2028
AlbuRxHuman Albumin
250 g/L (25% w/v) Solution for IV InfusionSingle dose. Type II glass vial with rubber stopper and yellow polypropylene flip-off disc (10 g in 50 mL Solution; 20 g in 100 mL solution) (Box of 1's) Box of 1's
Rx
CSL Behring AGSwitzerland
Zuellig Pharma Corporation
BR-1276
Jun 7, 2028
AlbuRxHuman Albumin
250 g/L (25% w/v) Solution for IV InfusionSingle dose. Type II glass vial with rubber stopper and yellow polypropylene flip-off disc (12.5 g in 50 mL solution; 25 g in 100 mL solution) (Box of 1’s)
Rx
CSL Behring LLCUSA
Zuellig Pharma Corporation
BR-1278
Jun 7, 2028
AlbuteinHuman Albumin
20% Solution for Infusion (IV)50 ml vial with administration set. (Box of 1's)
Rx
Grifols Biologicals LLCUSA
GD Distributors Inc.
BR-494
Apr 25, 2031
AlbuteinHuman Albumin
5% Solution for Injection for Infusion (IV)250 mL or 500 mL USP Type II glass vial with gray chlorobutyl rubber stopper and aluminum overseal with willow green-color plastic flip-off seal (Box of 1's).
Rx
Grifols Biologicals LLCU.S.A
Importer: GB Distributors, Inc.
BR-531
May 25, 2027
Albutein 25% SolutionHuman Albumin
25% Solution for Injection for Infusion (IV)50 mL or 100 mL USP Type II glass vial with gray overseal with chlorobutyl rubber stopper, and aluminum overseal with. willow green-color plastic flip-off seal (Box of 1's)
Rx
Grifols Biologicals LLCU.S.A
Importer: GB Distributors, Inc.
BR-463
May 25, 2027
HulbumineHuman Albumin
20% (0.2 g/mL) Solution for Intravenous Infusion50 mL Clear, Colorless Type I Glass Vial (Box of 1's)
Rx
Reliance Life Sciences Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambicare Pharmaceuticals Inc.
BRP-057-03
May 9, 2029
HumalHuman Albumin
20% (0.2 g/mL) Solution for Intravenous Infusion50 mL and 100 mL Clear, Colorless Type I Glass Vial (Box of 1's)
Rx
Reliance Life Sciences Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.
BRP-057
May 9, 2029
Human Albumin 20% Behring (Low Salt)Human Albumin
20% Solution for Infusion (IV)Infusion Bottle of 50 mL or 100 mL (Box of 1's)
Rx
CSL Behring GmbHGermany
Zuellig Pharma Corporation
BR-442
Jan 6, 2030
KedrialbHuman Albumin
200 g/L (20% w/v) Solution for IV Infusion50 mL Glass Vial (Box of 1's)
Rx
Kedrion S.P.A.Italy
Metro Drug, Inc.Importer: New Marketlink Pharmaceutical Corporation
BR-543
Feb 26, 2029
PlasbuteinHuman Albumin
20% (0.2g/mL) Solution for Infusion (I.V.)50 mL Type I Glass Vial (Box of 1's)
Rx
SK Plasma Co., Ltd.Republic of Korea
International Apex Pharmaceuticals, Inc.
BR-941
Apr 14, 2029
RescuerelHuman Albumin
20% (0.2 g/mL) Solution for Intravenous InfusionClear, colorless Type I glass vial x 50 mL and 100 mL (Box of 1's)
Rx
Reliance Life Sciences Pvt. Ltd.India
Diafarm Inc.Importer: Ambicare Pharmaceuticals Inc.
BRP-057-01
May 9, 2029
SeroalbuminHuman Albumin
200 g/L (20% w/v) Solution for Infusion (IV)50 mL and 100 mL USP Type I Glass vial with bromobutyl rubber stopper and Flip-off Aluminum seal (Box of 1's)
Rx
Virchow Biotech Pvt. Ltd.India
I.E. Medica, Inc.Trader: Virchow Healthcare Pvt. Ltd.
BRP-044
Feb 9, 2031
Zenalb 20Human Albumin
20% Solution for Injection (IV)Type II clear glass vial x 50mL (Box of 1's)
Rx
Bio Products Laboratory LimitedUnited Kingdom
Britton Distributions, Inc.
BR-488
Mar 3, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS ALBUMINEX 5% is a sterile, aqueous solution of human albumin (5% w/v i.e. 5 g/dL) for intravenous administration available as: 250 mL (12.5 g) single dose vial 500 mL (25 g) single dose vial ALBUMINEX 5% is a solution for infusion: ALBUMINEX 5% contains 5 g per dL of human albumin in 250 mL (12.5 g) and 500 mL (25 g) glass vials

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Suspicion of allergic or anaphylactic reactions requires immediate discontinuation of the injection and implementation of appropriate medical treatment (5.1)
  • Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the patient's volume status. Use with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient. (5.2)
  • Assess electrolytes, coagulation and hematology parameters, and hemodynamic status when albumin is administered (5.4)
  • Do not dilute with sterile water for injection (2.3, 5.5, 7.0)
  • This product is made from human plasma and may contain infectious agents, e.g. viruses and, theoretically, the Creutzfeldt-Jakob disease agent. (5.5)
5.1 Hypersensitivity Reactions

5.1 Hypersensitivity Reactions Suspicion of allergic or anaphylactic reactions, require immediate discontinuation of the infusion and implementation of appropriate medical treatment.

5.2 Hypervolemia

5.2 Hypervolemia Hypervolemia may occur if the dosage and rate of infusion are not adjusted to the patient's volume status. At the first clinical signs of cardiovascular overload (headache, dyspnea, jugular venous distention, increased blood pressure), the infusion must be slowed or stopped immediately. Use albumin with caution in conditions where hypervolemia and its consequences or hemodilution could represent a special risk to the patient.

Examples of such conditions are: Decompensated heart failure Hypertension Esophageal varices Pulmonary edema Hemorrhagic diathesis Severe anemia Renal and post-renal anuria

5.3 Laboratory Parameters

5.3 Laboratory Parameters When large volumes of albumin are being infused, control of coagulation parameters and hematocrit value is essential. Also, ensure adequate substitution of other blood constituents such as coagulation factors, electrolytes, platelets, and erythrocytes, as appropriate.

5.4 Clinical Hemodynamic Parameters

5.4 Clinical Hemodynamic Parameters The colloid osmotic pressure of ALBUMINEX 5% is about the same as plasma. The following parameters should be assessed during administration of ALBUMINEX 5%: Arterial blood pressure and pulse rate Central venous pressure Pulmonary artery occlusion pressure Urine output Electrolytes Hematocrit/hemoglobin

5.5 Pre-infusion

5.5 Pre-infusion preparation ALBUMINEX 5% must not be diluted with sterile water for injection as this may cause hemolysis in recipients. The product can be diluted in an isotonic solution (e.g., 5% dextrose in water or 0.9% sodium chloride) [see Dosage and Administration (2.2)].

5.6 Infectious Diseases

5.6 Infectious Diseases Albumin is a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases. A theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) is also considered extremely remote. No cases of transmission of viral diseases or CJD have ever been identified for ALBUMINEX 5%.

Drug interactions

Drug interactions (US label) US FDA label

7 DRUG INTERACTIONS Do not mix ALBUMINEX 5% with blood, blood components, protein hydrolysates, alcoholic solutions or other medicinal products. Although it is not usually necessary to dilute Albuminex 5%, if it should be necessary, it may be diluted with 0.9% saline or 5% dextrose. However, it can be administered, via a separate IV line, concomitantly with other parenterals.

Adverse reactions

Adverse reactions (US label) US FDA label

The most common adverse reactions are rigors, hypotension/decreased BP, tachycardia/increased heart rate, pyrexia, feeling cold (chills), nausea, vomiting, dyspnea/bronchospasm, rash/pruritus. Stop the infusion if anaphylaxis, with or without shock is observed. To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma, Inc. at 1-855-3KDRION (1-855-353-7466) or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

6.1 General

6.1 General In general, human albumin solutions are well-tolerated and no specific, clinically relevant alterations in organ function or coagulopathy have been substantiated. 26 The most common adverse reactions associated with infusion of human albumin solutions are rigors, hypotension/decreased BP, tachycardia/increased heart rate, pyrexia, feeling cold (chills), nausea, vomiting, dyspnea/bronchospasm, rash/pruritus. Reactions usually resolve when the infusion is slowed or stopped.

Anaphylaxis, with or without shock, may occur and in this situation, stop the infusion.

6.2 Clinical Trials Experience

6.2 Clinical Trials Experience No clinical studies were done using ALBUMINEX 5%.

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no data with ALBUMINEX 5% use in pregnant women to inform on drug-associated risk. Animal reproduction studies have not been conducted using ALBUMINEX 5%. It is not known whether ALBUMINEX 5% can cause fetal harm when administered to a pregnant woman or can affect fertility. ALBUMINEX 5% should be given to a pregnant woman only if clearly needed. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Mechanism of action

12.1 Mechanism of Action Human albumin accounts for more than half of the total protein in the plasma and represents about 10% of protein synthesis activity by the liver. The primary physiological function of albumin results from its contribution to plasma colloid oncotic pressure and transport function. Albumin stabilizes circulating blood volume and is a carrier of hormones, enzymes, medicinal products and toxins. Other physiological functions include antioxidant properties, free radical scavenging, and capillary membrane integrity.

US FDA label

Pharmacokinetics

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Albumin is distributed throughout the extracellular space and more than 60% of the body albumin pool is located in the extravascular fluid compartment. Albumin has a circulating life span of 15-20 days, with a turnover of approximately 15 g per day. The balance between synthesis and breakdown is normally achieved by feedback regulation.

Elimination is predominantly intracellular and due to lysosome proteases. In healthy subjects, less than 10% of infused albumin leaves the intravascular compartment during the first 2 hours following infusion. There is considerable individual variation in the effect of albumin on plasma volume. In some patients, the plasma volume can remain elevated for several hours.

In critically ill patients, however, albumin can leak out of the vascular space in substantial amounts at an unpredictable rate.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Albumin, Human 20%, 100 mL Bottle₱1,880.00–₱4,000.00Reference ₱1,880.00per bottleDPRI procurement range
Albumin, Human 20%, 50 mL Bottle₱1,522.00–₱2,389.00Reference ₱1,648.00per bottleDPRI procurement range
Albumin, Human 25%, 50 mL Bottle₱1,800.00–₱2,800.00Reference ₱2,400.00per bottleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Albumin, Human
PNF listingInj.: 20%, 50 mL and 100 mL bottle (IV, IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PNF listingInj.: 25%, 50 mL and 100 mL bottle (IV, IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PNF listingInj.: 25%, 50 mL plastic bag (IV, IV infusion)Restrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1); Limited indications or narrow spectrum of activity (PNF code 2)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. ALBUMINEX · BPL [US FDA-approved label, version 8, December 31, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8428d373-f4b1-4e3b-bb19-ea89048f7c79
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .